Capricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment Research

Capricor Therapeutics (NASDAQ:CAPR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.60 price target (up from $6.50) on shares of Capricor Therapeutics in a report on Friday, January 26th.

Capricor Therapeutics (NASDAQ:CAPR) traded up $0.09 during midday trading on Wednesday, reaching $2.04. 1,949,071 shares of the company’s stock traded hands, compared to its average volume of 639,203. Capricor Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $4.25. The stock has a market capitalization of $52.45, a price-to-earnings ratio of -3.09 and a beta of -4.66.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $107,000. Jane Street Group LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $190,000. Belpointe Asset Management LLC purchased a new stake in shares of Capricor Therapeutics during the third quarter valued at $249,000. Virtu KCG Holdings LLC grew its holdings in shares of Capricor Therapeutics by 571.9% during the second quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 152,614 shares during the last quarter. Finally, Brown Advisory Inc. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at $1,796,000. 4.05% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Capricor Therapeutics (CAPR) Rating Lowered to Hold at Zacks Investment Research” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/02/14/capricor-therapeutics-capr-rating-lowered-to-hold-at-zacks-investment-research.html.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply